Galhaut et al. evaluate the immunogenicity and efficacy of an inactivated whole virus COVID-19 vaccine in animal models. VLA2001 adjuvanted with alum and CpG 1018 generates polyfunctional Th1 cell responses and specific neutralizing antibodies to several SARS-CoV-2 variants of concern and protects macaques from viral replication and inflammation.
- Mathilde Galhaut
- Urban Lundberg
- Roger Le Grand
